Guillain-Barre syndrome is an acute autoimmune disorder in which the body attacks peripheral nerves outside the brain and spinal cord. In a typical presentation, muscle weakness and numbness begin in the feet and legs before ascending to the arms, chest, and face over several days or weeks. Nerve signaling slows down when protective coatings or underlying axons suffer damage, leading to lost tendon reflexes and diminished muscular control. Global estimates from medical registries indicate that roughly 1 to 2 people per 100,000 develop the condition each year in North America, Europe, and Asia. While acute nerve swelling can cause temporary flaccid paralysis and require ventilator support, early hospital care helps most people recover. [8]
How Guillain-Barre Syndrome Begins
French physicians Georges Guillain, Jean Alexandre Barré, and André Strohl first described the illness in Paris in 1916 after treating two soldiers who showed motor weakness and absent tendon reflexes. Earlier in 1859, French doctor Jean-Baptiste Octave Landry documented ten patients with ascending paralysis. Today neurologists classify the condition as an acute postinfectious polyradiculoneuropathy. [4]
Peripheral nerves link the spinal cord to limbs, skin, and organs, carrying sensory signals and muscle instructions. When an immune attack damages these pathways, electrical signals travel slowly or stop. In 2021, researcher N. L. Bragazzi and co-authors published Global Burden of Diseases Study data showing that 150,095 cases occurred globally in 2019, causing 44,407 years lived with disability. Annual risk rises by about 20% for every ten years of age. Studies in Europe and North America by J. J. Sejvar found higher rates in men than women, with an adult ratio of about 1.5 to 1. In Bangladesh, pediatric incidence reaches 3.25 cases per 100,000. [13]
Disease courses differ between patients. Some people feel mild tingling in their toes that clears without stopping them from walking. Others suffer sudden leg weakness that leaves them unable to stand within days. The Brighton Collaboration and the National Institute of Neurological Disorders and Stroke in the United States established criteria to help doctors separate Guillain-Barre syndrome from spinal cord injuries and toxic neuropathies. [7]
Infection Triggers and Molecular Mimicry
About two-thirds of patients recall a respiratory or bowel illness one to six weeks before weakness starts. The foodborne bacterium Campylobacter jejuni is the single most common trigger, found in roughly 30% of all cases in Europe and North America and up to 75% of axonal cases in China and Japan. Other recognized triggers include cytomegalovirus, Epstein-Barr virus, influenza, and Zika virus. Doctors in Colombia documented Zika clusters with facial paralysis during the 2015 outbreak in South America. [5]
Nerve researchers Nobuhiro Yuki and Hans-Peter Hartung described in the New England Journal of Medicine how an infection provokes nerve injury through molecular mimicry, where bacterial surface molecules share structural features with peripheral nerves. Lipopolysaccharides on the coat of Campylobacter jejuni resemble human GM1 and GD1a gangliosides located along nerve fibers. The immune system forms antibodies to eliminate the bowel bug, but these defense proteins mistakenly attach to human nerve targets. Complement proteins then coat the nerve, summoning macrophages that peel away the myelin sheath. [3]
Noninfectious events occasionally precede nerve damage. Case reports note onset after surgery, systemic lupus erythematosus, Hodgkin lymphoma, and cancer therapies using immune checkpoint inhibitors such as pembrolizumab and nivolumab. In children, Mycoplasma pneumoniae is a recognized respiratory antecedent. The syndrome is not contagious. It cannot pass from one person to another. [6]
Early Signs of Ascending Weakness
Early signs usually begin as tingling, pins and needles, or numbness in the toes and fingers. Patients feel deep aching or cramp-like pains in the calves, hips, back, and shoulders that hurt with gentle movement. Ankle and knee tendon reflexes diminish or vanish during the first days. Weakness then climbs upward from the legs to the trunk and arms. Most people notice both sides of the body weaken together. [8]
Weakness progresses over hours to days until reaching a plateau phase, with four weeks representing the classic outer boundary for acute decline. About 80% of patients reach maximum weakness within two weeks, whereas one in five worsens through the third or fourth week. Cranial nerve damage occurs in half of patients, causing bilateral facial droop, double vision, and difficulty swallowing. Chest muscles weaken in a quarter of patients, causing breathing failure that requires assisted mechanical ventilation in 20% to 30% of hospitalized adults, often needing admission to intensive care. Blood pressure swings and abnormal heart rhythms occur when the autonomic nervous system is disrupted. In some patients, heart pauses become so dangerous that doctors must insert a temporary pacemaker. [11]
Emergency medical evaluation is necessary when walking worsens quickly or swallowing becomes hard. Choking on liquids, slurred speech, and feeling faint when standing signal dangerous nerve dysfunction. Patient groups like GBS CIDP Foundation International and Inflammatory Neuropathies UK urge people to seek hospital care without delay. Quick admission protects against sudden breathing failure. [15]
Subtypes of Guillain-Barre Syndrome
Acute inflammatory demyelinating polyneuropathy, known as AIDP, is the classic form of Guillain-Barre syndrome and represents about 90% of cases in the United States and across Western Europe. In AIDP, white blood cells and antibodies attack the outer myelin sheath that insulates peripheral nerves. Demyelination slows nerve impulses, causing tingling and leg weakness that spreads upward. Most patients notice sensory changes before muscle weakness sets in. [5]
Axonal subtypes strike the central nerve wire rather than the myelin coat, leading to more profound weakness and slower healing. Acute motor axonal neuropathy, called AMAN, causes pure motor weakness without sensory loss and occurs often in northern China, Japan, and Mexico during summer months. Between 70% and 75% of AMAN patients show antibodies after Campylobacter jejuni enteritis, targeting gangliosides GM1, GD1a, and GalNac-GD1a. Nerve biopsies display Wallerian-like degeneration without heavy lymphocyte infiltration. About one-third of people with AMAN retain lively or exaggerated reflexes, which researchers link to anti-GM1 antibodies interfering with spinal interneurons. Another variant, acute motor-sensory axonal neuropathy, or AMSAN, strikes adult motor and sensory fibers, leading to marked muscle loss. [4]
Miller Fisher syndrome is a cranial variant described in 1956 by Canadian neurologist Charles Miller Fisher, marked by a classic triad of eye muscle paralysis, lost tendon reflexes, and poor coordination called ataxia. Neurologists link this condition to antibodies against the GQ1b ganglioside, which is concentrated in oculomotor nerves controlling eye movement. More than 85% of people with Miller Fisher syndrome test positive for anti-GQ1b antibodies in their blood. Most patients recover their eye movement and balance within six months. [12]
Hospital Testing and Lumbar Puncture
Doctors diagnose the condition through physical exams that detect progressive symmetrical weakness and missing deep tendon reflexes in the limbs. Because early signs resemble conditions like myasthenia gravis, botulism, and tick paralysis, physicians run blood work, liver function tests, and muscle enzymes to rule out other causes. Ten-step diagnostic guidelines published in Nature Reviews Neurology by Sonja E. Leonhard and colleagues emphasize that bilateral muscle weakness remains the foundation of diagnosis. [2]
A lumbar puncture provides confirmation by showing albuminocytologic dissociation, where protein in the cerebrospinal fluid is elevated while white blood cells stay normal. Cerebrospinal protein climbs above 400 milligrams per liter, or 45 milligrams per deciliter, while cell counts stay at or below 10 mononuclear white cells per microliter. However, spinal protein can remain normal in the first week after weakness appears. Doctors may repeat the spinal tap two weeks later if symptoms persist. [7]
Nerve conduction studies and needle electromyography test whether peripheral nerves carry electrical signals properly. In AIDP, tests show delayed distal latencies, slow conduction speeds, and conduction blocks. In AMAN, muscle response amplitudes drop below 20% of normal without conduction slowing. Guidelines from the European Academy of Neurology and the Peripheral Nerve Society advise doctors to assess breathing strength using bedside vital capacity and negative inspiratory force. When negative inspiratory force nears 20 centimeters of water, patients need intensive care admission. [1]
First-Line Hospital Treatments
Two proven treatments help speed up motor recovery: intravenous immunoglobulin (IVIg) and plasma exchange, also known as plasmapheresis. Both therapies remove or neutralize harmful antibodies circulating in the blood. A Cochrane systematic review led by Richard A. Hughes confirmed that IVIg and plasma exchange work equally well in hastening recovery for patients with severe weakness. IVIg is often chosen because it is easier to give through a simple vein drip. [14]
Plasma exchange filters the patient’s blood through an apheresis machine to pull out damaging autoantibodies and complement proteins before returning red cells with clean replacement albumin. A standard treatment course involves five plasma exchanges over one to two weeks. Giving IVIg right after plasma exchange brings no added benefit. Clinical trials also show that steroid medications like prednisolone do not speed up recovery and may hinder natural nerve healing. [8]
Intensive care units prevent medical complications while nerves recover. Patients with forced vital capacity falling under 20 milliliters per kilogram receive breathing tube placement and ventilator support. Nurses give low-molecular-weight heparin and apply leg compression garments to prevent deep vein thrombosis and pulmonary embolism in bedbound patients. Physical therapists move joints to stop muscle contractures, while speech therapists check swallowing to guard against pneumonia. [4]
Long-Term Recovery Pathways
Once the illness stops worsening, patients reach a plateau where weakness stays steady for days or weeks before nerves begin to heal. Schwann cells rebuild damaged myelin coats, allowing electrical impulses to travel normally to muscles again. Research studies show that 80% of patients walk independently by six months after symptom onset. In children, recovery is even better: between 90% and 95% make a full motor recovery within three to twelve months. [6]
About 20% of adults live with lingering nerve problems, including weak foot muscles, numb toes, and nerve pain. Roughly 5% suffer severe disability that prevents unassisted daily living. Long-term fatigue is the most common lingering symptom, often bothering patients for years even after muscle strength returns. Neurologists at Erasmus University Medical Center in Rotterdam built the Erasmus GBS Outcome Score (EGOS), using patient age, diarrhea history, and muscle scores to predict walking recovery at six months. [5]
Global mortality stands between 3% and 7.5%, with modern intensive care keeping death rates between 3% and 5% in high-resource settings. Deaths stem from heart arrest, acute respiratory distress syndrome, pulmonary emboli, or blood infections during long hospital stays. In a Dutch cohort studied by B. van den Berg and colleagues, two-thirds of deaths happened during recovery from medical complications. About 5% to 10% of patients suffer a relapse weeks after treatment, requiring a second course of IVIg or plasma exchange. [4]
Can Vaccines Trigger Guillain-Barre Syndrome?
Public health authorities track nerve conditions after immunizations, finding that absolute risks stay small. The strongest historical link occurred in the United States during the 1976 swine flu campaign (H1N1 A/NJ/76), where vaccine recipients developed 8.8 cases per million doses among 45 million people vaccinated, representing an 8.8-fold rise over baseline rates. In contrast, modern seasonal flu shots carry a far lower risk of about 0.75 to 1 excess case per million doses. Health agencies emphasize that catching natural influenza brings a much higher risk of Guillain-Barre syndrome than getting the annual flu shot. [11]
Safety surveillance for other vaccines has turned up isolated statistical signals while affirming overall safety. In March 2021, the U.S. Food and Drug Administration required manufacturer GlaxoSmithKline to add a warning to the prescribing information for Shingrix, an adjuvanted shingles vaccine for adults aged 50 and older. An observational study of 3,729,863 doses given to 2,113,758 Medicare beneficiaries aged 65 and older found an estimated three excess cases per million doses within a 42-day post-vaccination window. The FDA determined that evidence showed an association but was insufficient to prove causation, concluding that vaccine benefits continue to outweigh risks. [9]
European regulators conducted similar reviews during the COVID-19 pandemic. The European Medicines Agency and its Pharmacovigilance Risk Assessment Committee (PRAC) listed Guillain-Barre syndrome as a very rare potential complication of the adenovirus vector vaccine made by Janssen, evaluating 108 cases worldwide among more than 21 million vaccinated people. A warning was also placed on Vaxzevria made by AstraZeneca. By comparison, surveillance in the Vaccine Safety Datalink found no link to mRNA vaccines such as Comirnaty from Pfizer-BioNTech or Spikevax from Moderna. Health officials advise patients to seek prompt medical care if unusual limb weakness appears after vaccination. [10]
- ACADEMIC JOURNAL van Doorn, P. A., Van den Bergh, P. Y. K., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Attarian, S., Blomkwist‐Markens, P. H., Cornblath, D. R., Goedee, H. S., Harbo, T., Jacobs, B. C., Kusunoki, S., Lehmann, H. C., Lewis, R. A., Lunn, M. P., Nobile‐Orazio, E., Querol, L., Rajabally, Y. A., Umapathi, T.,. Willison, H. J. (2023). European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome. European Journal of Neurology, 30(12), 3646-3674. [Article Link]
- ACADEMIC JOURNAL Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., Kusunoki, S., Pardo, C. A., Reisin, R., Sejvar, J. J., Shahrizaila, N., Soares, C., Umapathi, T., Wang, Y., Yiu, E. M.,. Jacobs, B. C. (2019). Diagnosis and management of Guillain-Barré syndrome in ten steps. Nature Reviews Neurology, 15(11), 671-683. [Article Link]
- ACADEMIC JOURNAL Yuki, N., & Hartung, H.-P. (2012). Guillain-Barré syndrome. New England Journal of Medicine, 366(24), 2294-2304. [Article Link]
- WEBSITE Medscape. (2026). Guillain-Barre Syndrome: Practice Essentials, Background, Pathophysiology. [Article Link]
- WEBSITE Medscape. (2026). Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Background, Epidemiology, Etiology. [Article Link]
- WEBSITE Medscape. (2026). Pediatric Guillain-Barre Syndrome: Background, Diagnostic Criteria, Epidemiology. [Article Link]
- WEBSITE Patient.info. (2022). Guillain-Barré syndrome: Professional Reference. [Article Link]
- WEBSITE MedlinePlus. (2025). Guillain-Barre syndrome: MedlinePlus Medical Encyclopedia. [Article Link]
- PRESS RELEASE U.S. Food and Drug Administration. (2021). FDA Requires a Warning about Guillain-Barré Syndrome (GBS) be Included in the Prescribing Information for Shingrix. [Article Link]
- PRESS RELEASE European Medicines Agency. (2021). COVID-19 Vaccine Janssen: Guillain-Barré syndrome listed as a very rare side effect. [Article Link]
- WEBSITE Wikipedia contributors. (n.d.). Guillain–Barré syndrome. [Article Link]
- WEBSITE Wikipedia contributors. (n.d.). Miller Fisher syndrome. [Article Link]
- ACADEMIC JOURNAL Bragazzi, N. L., Kolahi, A. A., Nejadghaderi, S. A., Lochner, P., Brigo, F., Naldi, A., Lanteri, P., Garbarino, S., Sullman, M. J. M., Dai, H., Wu, J., Kong, J. D., Jahrami, H., Sohrabi, M. R., & Safiri, S. (2021). Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019. Journal of Neuroinflammation, 18(1), 264. [Article Link]
- ACADEMIC JOURNAL Hughes, R. A., Swan, A. V., & van Doorn, P. A. (2014). Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews, 2019(10), CD002063. [Article Link]
- WEBSITE GBS | CIDP Foundation International. (2026). Intro to Guillain-Barré Syndrome (GBS). [Article Link]
Cover image: Sugita Genpaku / Nakagawa Jun'an / Maeno Ryōtaku / Wikimedia Commons, Public domain
